Department of Pharmaceutical Sciences-Drug Development Division, College of Pharmacy, University of Kentucky, 789 S. Limestone Street, Lexington, KY 40536-0596, USA.
Lung. 2012 Jun;190(3):251-62. doi: 10.1007/s00408-011-9360-x. Epub 2012 Jan 25.
Therapeutic liposomal powders (i.e., lipospheres and proliposomes) for dry powder inhalation aerosol delivery, formulated with phospholipids similar to endogenous lung surfactant, offer unique opportunities in pulmonary nanomedicine while offering controlled release and enhanced stability. Many pulmonary diseases such as lung cancer, tuberculosis (TB), cystic fibrosis (CF), bacterial and fungal lung infections, asthma, and chronic obstructive pulmonary disease (COPD) could greatly benefit from this type of pulmonary nanomedicine approach that can be delivered in a targeted manner by dry powder inhalers (DPIs). These delivery systems may require smaller doses for efficacy, exhibit reduced toxicity, fewer side effects, controlled drug release over a prolonged time period, and increased formulation stability as inhaled powders. This state-of-the-art review presents these novel aspects in depth.
用于干粉吸入气溶胶递送的治疗性脂质体粉末（即脂质体和前脂质体），其配方中的磷脂与内源性肺表面活性剂相似，为肺部纳米医学提供了独特的机会，同时提供了控释和增强的稳定性。许多肺部疾病，如肺癌、肺结核（TB）、囊性纤维化（CF）、细菌和真菌感染、哮喘和慢性阻塞性肺疾病（COPD），都将极大地受益于这种肺部纳米医学方法，该方法可以通过干粉吸入器（DPIs）以靶向方式递送。这些递送系统可能需要较小的剂量才能有效，表现出降低的毒性、更少的副作用、在延长的时间段内控制药物释放，以及增加作为吸入粉末的配方稳定性。这篇最先进的综述深入介绍了这些新的方面。
